Status:
COMPLETED
A Study to Compare the Efficacy and Safety of Ziprasidone and Risperidone for the Treatment of Schizophrenia in Chinese Patients
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Schizophrenia
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to compare the efficacy and safety of ziprasidone and risperidone for the treatment of schizophrenia in Chinese patients
Eligibility Criteria
Inclusion
- Hospitalized patients with schizophrenia
- Miminum PANSS score of 60 when randomized
Exclusion
- Planned, regular use of antipsyhotics within 1 week of randomization
- Previous treatment with risperidone that resulted in intolerance or lack of response to risperidone
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2005
Estimated Enrollment :
242 Patients enrolled
Trial Details
Trial ID
NCT00645372
Start Date
July 1 2004
End Date
May 1 2005
Last Update
February 21 2021
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Beijing, China, 100083
2
Pfizer Investigational Site
Beijing, China, 100088
3
Pfizer Investigational Site
Guangzhou, China, 510370
4
Pfizer Investigational Site
Nanjing, China, 210029